MIS-C in neonates, although rare, is associated with morbidity and mortality. MIS-C in neonates may present with a wide variety of signs and symptoms. Early recognition is paramount. The mainstay of treatment involves IVIG and corticosteroids. More clinical trials are necessary to study the efficacy of various treatment modalities. Long-term follow-up is necessary to elucidate potential sequelae.